Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Янв. 22, 2025
Molecular
imaging
technologies
have
significantly
transformed
cancer
research
and
clinical
practice,
offering
valuable
tools
for
visualizing
understanding
the
complex
tumor
immune
microenvironment.
These
allow
non-invasive
examination
of
key
components
within
microenvironment,
including
cells,
cytokines,
stromal
providing
crucial
insights
into
biology
treatment
responses.
This
paper
reviews
latest
advancements
in
molecular
imaging,
with
a
focus
on
its
applications
assessing
interactions
Additionally,
challenges
faced
by
are
discussed,
such
as
need
highly
sensitive
specific
agents,
issues
data
integration,
difficulties
translation.
The
future
outlook
emphasizes
potential
to
enhance
personalized
through
integration
artificial
intelligence
development
novel
probes.
Addressing
these
is
essential
fully
realizing
improving
diagnosis,
treatment,
patient
outcomes.
Journal of Hematology & Oncology,
Год журнала:
2024,
Номер
17(1)
Опубликована: Июнь 4, 2024
Abstract
Pancreatic
cancer
is
a
major
cause
of
cancer-related
death,
but
despondently,
the
outlook
and
prognosis
for
this
resistant
type
tumor
have
remained
grim
long
time.
Currently,
it
extremely
challenging
to
prevent
or
detect
early
enough
effective
treatment
because
patients
rarely
exhibit
symptoms
there
are
no
reliable
indicators
detection.
Most
advanced
spreading
that
difficult
treat,
treatments
like
chemotherapy
radiotherapy
can
only
slightly
prolong
their
life
by
few
months.
Immunotherapy
has
revolutionized
pancreatic
cancer,
yet
its
effectiveness
limited
tumor's
immunosuppressive
hard-to-reach
microenvironment.
First,
article
explains
microenvironment
highlights
wide
range
immunotherapy
options,
including
therapies
involving
oncolytic
viruses,
modified
T
cells
(T-cell
receptor
[TCR]-engineered
chimeric
antigen
[CAR]
T-cell
therapy),
CAR
natural
killer
cell
therapy,
cytokine-induced
cells,
immune
checkpoint
inhibitors,
immunomodulators,
vaccines,
strategies
targeting
myeloid
in
context
contemporary
knowledge
future
trends.
Lastly,
discusses
main
challenges
ahead
immunotherapy.
Advanced Materials,
Год журнала:
2024,
Номер
36(25)
Опубликована: Март 12, 2024
Abstract
The
dense
extracellular
matrix
(ECM)
in
solid
tumors,
contributed
by
cancer‐associated
fibroblasts
(CAFs),
hinders
penetration
of
drugs
and
diminishes
their
therapeutic
outcomes.
A
sequential
treatment
strategy
remodeling
the
ECM
via
a
CAF
modifier
(dasatinib,
DAS)
is
proposed
to
promote
an
immunogenic
cell
death
(ICD)
inducer
(epirubicin,
Epi)
apoptotic
vesicles,
ultimately
enhancing
efficacy
against
breast
cancer.
Dendritic
poly(oligo(ethylene
glycol)
methyl
ether
methacrylate)
(POEGMA)‐based
nanomedicines
(poly[OEGMA‐Dendron(G2)‐Gly‐Phe‐Leu‐Gly‐DAS]
(P‐DAS)
poly[OEGMA‐Dendron(G2)‐hydrazone‐Epi]
(P‐Epi))
are
developed
for
delivery
DAS
Epi,
respectively.
P‐DAS
reprograms
CAFs
reduce
collagen
downregulating
anabolism
energy
metabolism,
thereby
reducing
deposition.
regulated
can
enhance
tumor
P‐Epi
strengthen
its
ICD
effect,
leading
amplified
antitumor
immune
response.
In
cancer‐bearing
mice,
this
approach
alleviates
barrier,
resulting
reduced
burden
increased
cytotoxic
T
lymphocyte
infiltration,
more
encouragingly,
synergizes
effectively
with
anti‐programmed
1
(PD‐1)
therapy,
significantly
inhibiting
growth
preventing
lung
metastasis.
Furthermore,
systemic
toxicity
barely
detectable
after
P‐Epi.
This
opens
new
avenue
treating
desmoplastic
tumors
metabolically
targeting
overcome
barrier.
International Journal of Oncology,
Год журнала:
2024,
Номер
65(3)
Опубликована: Июль 25, 2024
Globally,
colorectal
cancer
(CRC)
is
the
third
most
common
type
of
cancer.
CRC
has
no
apparent
symptoms
in
early
stages
disease,
and
patients
receive
a
confirmed
diagnosis
middle
or
late
disease
stages.
The
incidence
continues
to
increase,
affected
population
tends
be
younger.
Therefore,
determining
how
achieve
an
treatment
become
top
priority
for
prolonging
patient
survival.
Myeloid‑derived
suppressor
cells
(MDSCs)
are
group
bone
marrow‑derived
immuno‑negative
regulatory
that
divided
into
two
subpopulations,
polymorphonuclear‑MDSCs
monocytic‑MDSCs,
based
on
their
phenotypic
similarities
neutrophils
monocytes,
respectively.
These
can
inhibit
immune
response
promote
cell
metastasis
tumour
microenvironment
(TME).
A
large
aggregation
MDSCs
TME
often
marker
poor
prognosis
inflammatory
diseases
intestine
(such
as
colonic
adenoma
ulcerative
colitis).
In
present
review,
classification
first
discussed.
Then,
amplification,
role
metastatic
mechanism
described,
focusing
genes,
gene
modifications,
proteins
intestinal
microenvironment.
Finally,
progress
CRC‑targeted
therapies
aim
modulate
quantity,
function
structure
summarized
hope
identifying
potential
screening
markers
improving
therapeutic
options.
Lipids in Health and Disease,
Год журнала:
2025,
Номер
24(1)
Опубликована: Янв. 13, 2025
Lipid
metabolism
in
cancer
is
characterized
by
dysregulated
lipid
regulation
and
utilization,
critical
for
promoting
tumor
growth,
survival,
resistance
to
therapy.
Pancreatic
(PC)
a
highly
aggressive
malignancy
of
the
gastrointestinal
tract
that
has
dismal
5-year
survival
rate
less
than
10%.
Given
essential
function
pancreas
digestion,
progression
severely
disrupts
its
function.
Standard
treatments
PC
such
as
surgical
resection,
chemotherapy,
radiotherapy.
However,
these
therapies
often
face
significant
challenges,
including
biochemical
recurrence
drug
resistance.
limitations,
new
therapeutic
approaches
are
being
developed
target
metabolism.
Dysregulation
cholesterol
biosynthesis
alterations
fatty
acids
(FAs),
palmitate,
stearate,
omega-3,
omega-6,
have
been
observed
pancreatic
cancer.
These
lipids
serve
energy
sources,
signaling
molecules,
components
cell
membranes.
Their
accumulation
fosters
an
immunosuppressive
microenvironment
supports
proliferation
metastasis.
Moreover,
dysregulation
within
immune
cells,
particularly
T
impairs
surveillance
weakens
body's
defenses
against
Abnormal
also
contributes
PC.
Despite
targeting
may
offer
promising
strategy.
By
enhancing
peroxidation,
induction
ferroptosis—a
form
regulated
death—could
impair
cells
hinder
disease
progression.
Journal of Hematology & Oncology,
Год журнала:
2025,
Номер
18(1)
Опубликована: Фев. 17, 2025
Cancer
continues
to
be
a
major
global
health
burden,
with
high
morbidity
and
mortality.
Building
on
the
success
of
immune
checkpoint
inhibitors
adoptive
cellular
therapy,
cancer
vaccines
have
garnered
significant
interest,
but
their
clinical
remains
modest.
Benefiting
from
advancements
in
technology,
many
meticulously
designed
shown
promise,
warranting
further
investigations
reach
full
potential.
hold
unique
benefits,
particularly
for
patients
resistant
other
therapies,
they
offer
ability
initiate
broad
durable
T
cell
responses.
In
this
review,
we
highlight
antigen
selection
vaccines,
introduce
responses
induced
by
propose
strategies
enhance
vaccine
immunogenicity.
Furthermore,
summarize
key
features
notable
advances
various
platforms.
Lastly,
delve
into
mechanisms
tumor
resistance
explore
potential
benefits
combining
standard
treatments
immunomodulatory
approaches
improve
efficacy.
